The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury

BACKGROUND: The novel nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone holds promise to be safe and efficient in the treatment of patients with heart failure and/or chronic kidney disease. However, its effects on vascular function remain elusive. PURPOSE: The aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutzmann, Jochen, Musmann, Robert-Jonathan, Haertlé, Marco, Daniel, Jan-Marcus, Sonnenschein, Kristina, Schäfer, Andreas, Kolkhof, Peter, Bauersachs, Johann, Sedding, Daniel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605005/
https://www.ncbi.nlm.nih.gov/pubmed/28926607
http://dx.doi.org/10.1371/journal.pone.0184888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605005/
https://www.ncbi.nlm.nih.gov/pubmed/28926607
http://dx.doi.org/10.1371/journal.pone.0184888

Ejemplares similares